Pharmafile Logo
Pharmafocus logo
Advanced Search

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023
Research and Development Musculo-skeletal disorder, NMD Pharma, clinical trial, spinal muscular atrophy

NMD Pharma has announced that the first patient has been dosed in its phase 2 clinical trial for its CIC-1 …

News

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023
Business Services Alfasigma, Gastrointestinal tract, acquisition

Alfasigma and Intercept Pharmaceuticals have announced that they have entered into a definitive merger agreement, meaning Alfasigma will acquire Intercept …

News

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023
Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi

Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …

News

Acesion Pharma raises €45m series B funding

September 26, 2023
Business Services Acesion Pharma, Cardiology, atrial fibrillation, series B financing

Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round. This financing was co-led by …

News

CDC Advisory Committee recommends Pfizer’s RSV vaccine

September 25, 2023
Medical Communications Abrysvo, Immunology, Pfizer, RSV

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has …

News

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023
Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …

News

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023
Medical Communications FDA, Haematology, Nexcella, amyloidosis

Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NXC-201 for …

News

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

News

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023
Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …

News

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023
Medical Communications European Commission, Oncology, Orserdu, breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …

News

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023
Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …

News

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023
Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …

News

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023
Medical Communications Dermatology, EC, Litfulo, alopecia

Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent …

News

BioNTech and CEPI partner for development of mRNA mpox vaccine

September 19, 2023
Research and Development BioNTech, CEPI, Immunology, mpox

BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a partnership to advance the development of mRNA-based vaccine …

News

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

September 18, 2023
Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …

News

Astellas plans to invest over €330m in new facility in Ireland

September 18, 2023
Manufacturing and Production Astellas Pharma, Ireland, Pharmacy, facility, manufacturing

Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at …

News

GSK and Save the Children extend partnership for unvaccinated children

September 15, 2023
Medical Communications GSK, Immunology, childhood vaccination, vaccines

GSK and Save the Children have announced that they will be renewing their partnership for an additional five years. GSK …

News

BMS shares new research and development  plans at the company’s R&D day

September 15, 2023
Research and Development BMS, Pharmacy, R&D, development, research

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, US, in order to discuss …

News

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

September 14, 2023
Sales and Marketing License Agreement, Neurology, Pharmazz, Sun Pharma, Tyvalzi, sovateltide

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a license agreement with Pharmazz in …

News

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

September 14, 2023
Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025